Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Remember the good ole days...
https://www.prnewswire.com/news-releases/scopus-biopharma-licenses-novel-immuno-oncology-gene-therapy-drug-from-city-of-hope-a-cancer-center-in-los-angeles-california-301074782.html
... and then...lawsuits....restraining order applications.... and more lawsuits.
Is the brawl over?
Is Phase I still on deck for May?
Get it together Scopus mgmt.
Thank you
Pivotal next few months for this company, imo.
If the Board can come together and get a couple of high profile new independent board members, and get back under Nasdaq compliance, this could do well.
I'm thinking somebody from the Anderson Cancer Clinic or the like.
However, if these guys continue to scrap away about like children, then we could be headed to a dime.
tsk tsk Scopus mgmt.
The Registrant expects to report a material increase in net loss, key components of which are set forth below, for the year ended December 31, 2021, as compared to a net loss of approximately $11 million for the year ended December 31, 2020. The net loss for the year ended December 31, 2021 is attributable principally to: (a) approximately $15 million of research and development expenses, including acquired in-process research and development expensed in connection with a key acquisition and (b) approximately $13 million of general and administrative expenses, including an aggregate of approximately $8 million of fees, costs and/or expenses relating to (i) a proxy contest for the 2021 Annual Meeting of Stockholders and related proceedings, including an action pursuant to Section 225 of the Delaware General Corporation Law and (ii) additional related litigation by or against the participants engaged in the proxy contest and other litigation by parties associated and/or acting with such participants. The amount set forth in (a) above includes non-cash expenses of approximately $12.6 million. In addition, certain of the amounts described in (b) above include accruals recorded in the year ended December 31, 2021. Subsequent to December 31, 2021, the Registrant has been negotiating with various parties for a reduction in certain of the amounts included in (b) above. Any reduction would be reflected as a reduction in accounts payable and accrued expenses in the period such reduction is recognized. As a result of such negotiations, on January 31, 2022, the Registrant recognized a reduction in accounts payable and accrued expenses which it expects to be reflected in its financial statements for the period ended March 31, 2022. There can be no assurance that the Registrant will be successful in negotiating any additional or material reductions.
They have until May2/22 to submit their "PLAN" for compliance regarding the independent directors issue.
Actions speak volumes and in this instance Messr. Laster, imo, is making changes that will benefit shareholder value.
NYS Court of Appeals Holds Criminally Usurious Loans Void Ab Initio
https://www.jdsupra.com/legalnews/nys-court-of-appeals-holds-criminally-8056560/
Could be applicable here as well, if the derivative financing shenanigans had exorbitant terms, and the issuing party, executed said exorbitant terms.
No doubt, damages to shareholder value/Scopus BioPharma reputation has been done.
Culpable parties need to be held accountable, imo.
All, in my opinion.
"On October 26, 2021, Dr. Laster and Messrs. Sanghrajka and Hopper (collectively, the “Plaintiffs”) filed a stockholder derivative lawsuit, purportedly on behalf of the Company, against all of the other members of the Company’s Board and certain of their affiliates in the Chancery Court (the “Derivative Complaint”). The Derivative Complaint alleges, among other things, that certain directors (the “Management Directors”) have wasted and diverted corporate assets, and that the other directors (the “Independent Directors”), excluding Messrs. Sanghrajka and Hopper, failed to stop the Management Directors from taking such actions. The Plaintiffs assert that they did not make demand upon the Company’s Board because demand would have been futile, notwithstanding the fact that five of the Company’s nine directors, including Mr. Hopper, are independent. On November 12, 2021, the Company filed a motion to dismiss the Derivative Complaint for failure to make a pre-suit demand on its Board."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1772028/000141057821000171/scps-20210930x10q.htm#Item3DefaultsUponSeniorSecurities_467199
Let's hope that Phase I does not experience any further delays.
https://clinicaltrials.gov/ct2/show/study/NCT04995536
After some review, no,i don't think Laster is the problem.
It's a complicated dispute but it appears that Laster took exception to the derivative financing shenanigans. That's what has driven the stock price down, imo.
Laster knows the value of the tech and the IP and it appears personal for him to get control back and get things on the right track.
AIMHO.
Watching for the following:
1. New accounting firm.
2. 10 - K Annual Report.
3. Any updates on any of the research and technology Scopus BioPharma is undertaking including the Phase 1 Study.
Complicated, but interesting company, lotsa passion here.
Something tells me the technology and IP portfolio is dramatically important in the field of medicine.
Messr. Laster's actions speak of a high degree of concern for the future of Scopus BioPharma. ALL, imo.
Thank you.
Bids building into the close.
Good volume continuation = accumulation.
Many high profile institutions at the conference.
Check it out here:
https://tlr-prr-targeted-therapies.com/whats-on/speakers/
schedule:
https://tlr-prr-targeted-therapies.com/whats-on/agenda/day-one/
A special THANK YOU to Scopus mgmt. for the update.
Nice to hear from you!
**ATTENTION PLEASE - NEWS OUT**
https://ca.finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-biotherapeutics-003000841.html
Scopus BioPharma Inc.
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on
TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting Therapies Summit, to be held virtually from March 22-24, 2022.
Duet BioTherapeutics is a wholly-owned subsidiary of Scopus. Dr. Horsager is also President — Immuno-Oncology of Scopus.
Dr. Horsager’s presentation will be part of the Rationale & Progress in Novel Methods of Targeting STING & TLR session. Dr. Horsager will present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology.
Duet BioTherapeutics was launched in September 2021 by Scopus BioPharma to integrate the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. The Duet Platform relies on a novel approach to immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The unique mechanism-of-action of these synthetic oligonucleotides comes from simultaneously targeting two intracellular immune pathways – signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor, and toll-like receptor 9 (TLR9). The targeted inhibition of STAT3 reawakens immune cells and allows for the full potential of TLR9-driven innate and adaptive immune responses.
The Duet Platform is comprised of three distinctive complementary CpG-STAT3 inhibitors:
RNA silencing
CpG-STAT3siRNA
(“DUET-01”)
Antisense
CpG-STAT3ASO
(“DUET-02”)
DNA-binding inhibitor
CpG-STAT3decoy
(“DUET-03”)
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file an IND for DUET-02 in Q4 2022 in advanced solid malignancies, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.
Details of the study here:(underlined is what makes Scopus's approach unique, imo.)
https://www.clinicaltrials.gov/ct2/history/NCT04995536?V_7=View#StudyPageTop
"Brief Summary: This phase I trial identifies the best dose and side effects of CpG-STAT3 siRNA CAS3/SS3 (CAS3/SS3) in combination with localized radiation therapy in treating patients with B-cell non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). CAS3/SS3 simultaneously targets two molecules, TLR9 receptor and STAT3. This investigational drug combines a CpG oligonucleotide and an siRNA in one molecule that act together to interfere with the ability of the cancer cells to grow. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving CAS3/SS3 with localized radiation therapy may kill more cancer cells.
Detailed Description:
PRIMARY OBJECTIVES:
I. Determine the recommended phase 2 dose (RP2D) of CAS3/SS3 when given in combination with local fixed-dose radiation therapy (RT).
II. Evaluate the safety and feasibility of intratumoral injections of CAS3/SS3 when combined with local fixed-dose RT, by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration.
SECONDARY OBJECTIVES:
I. Characterize the clinical activity (overall and per dose level) of CAS3/SS3 through the assessment of disease response, and response duration. (Clinical) II. Characterize the biologic activity (overall and per dose level) of CAS3/SS3 when combined with local fixed-dose RT by assessing. (Biologic [Immunologic Correlative Studies]) IIa. Silencing of the STAT3 gene and its key downstream genes. IIb. Local and systemic immune responses, including: evidence/extent of immune cell intratumoral infiltration, immune cell activation within the tumor and in the peripheral blood, and changes in proinflammatory mediators in plasma.
OUTLINE:
Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
After completion of study treatment, patients are followed up every 3 months."
Track the Phase I Study here:
https://www.clinicaltrials.gov/ct2/show/record/NCT04995536?term=scopus+biopharma&recrs=ab&cond=Cancer&cntry=US&draw=2&rank=1
History of Changes here:
https://www.clinicaltrials.gov/ct2/history/NCT04995536
Go here first for checking Delaware case/search by name/disclaimer/ fill in detail.
https://courtconnect.courts.delaware.gov/cc/cconnect/ck_public_qry_main.cp_main_idx
An update would be appreciated, either on the court case or on any advancement with the technology.
Thanks in advance.
Last at 0.8205 + .1812
Nice day here today!!
Excellent information here:
https://scopusbiopharma.com/launch-of-duet-therapeutics/
SCOPUS UN-RESOLVED CASES:
https://courtconnect.courts.delaware.gov/cc/cconnect/ck_public_qry_cpty.cp_personcase_details_idx
SCOPUS RESOLVED CASES:
https://www.pacermonitor.com/public/case/41854881/Scopus_BioPharma_Inc_v_Laster_et_al
Case Filed: Sep 15, 2021
Terminated: Sep 25, 2021
https://www.pacermonitor.com/public/case/42117888/Scopus_Biopharma,_Inc_v_Hopper_et_al
Case Filed: Oct 03, 2021
NOTICE OF VOLUNTARY DISMISSAL filed January 18/22
Before the sun slips under the horizon this Friday night, may peace reign between Scopus and the Laster family, amen.
Real Time
Bid .7251 Ask .7275
Friday's have been good here lately!
imho, summthing's up.
Volume rising.
Just for review the September/21 me-leee started on Sept.15/21, included a request for a temporary restraining order against Laster Family Partners (his daughters) , denied, and concluded on Saturday Sept.25/21 after which, all parties went out for dinner, imo.
https://www.pacermonitor.com/public/case/41854881/Scopus_BioPharma_Inc_v_Laster_et_al
I hope these guys can get over the Delaware case in the same fashion.
We need an update Scopus.
Thanks in advance.
AH close of .80!!
Nice set up for Monday morning.
NICE VOLUME !! coupled with a nice price uptick.
(next week might be interesting)
Thank you.
No PM.
That case was terminated September 25/21
https://www.pacermonitor.com/public/case/41854881/Scopus_BioPharma_Inc_v_Laster_et_al
They then went and filed in the Delaware Court of Chancery, it's difficult to find documents on that.
The company is waiting on the decision which will decide the results of the annual meeting.
I don't think they have a chance.
Your welcome.
Level II not looking good.
Company may as well stay quiet until the family dispute is settled.
So ordered.
Your Welcome.
Does anybody know what happened at the case conference of January 28/22?
I don't see anything filed on the case docket report yet
Thanks in advance
Is the meeting over?
I just mailed my voting card today, is that too late?
Agree 100%.
Hopefully, (speculating), todays security registration is part of a settlement to the dispute.
The fact that these guys are already fighting over things tells me that they have something significant.
If they can resolve the dispute, SCPS could explode, imo.
https://newsfilter.io/a/54b4b4399f69ecdc454a1b9dafb88a8c
IMO, Morris Laster is the one scamming the company and shareholders here. Why can’t he prove at the annual stockholder meeting that he still has all 6 million beneficiary shares par $0.001? Once the majority shareholders vote against him in the upcoming meeting share price will begin to reflect true value of the company. It could be a major catalyst here IMO
Still here at an average of 3.50. This will go to at least 10 when the time is right IMO…
I added more today. My new average is 3.52. Massive orders showed up on the bid this afternoon after it bounced off 3.37. Smart money loading? Shorts covering? I sense a big bounce is near IMO
5,000 shares ask slap at 3.52 just now!!!
Lots of buying today...Still here at an average of 3.58...
Back in this at 3.73. SCPS starting to turn into an ATM!
Of interest to SCPS shareholders
https://finance.yahoo.com/news/scopus-biopharma-retaining-counsel-investigate-203000482.html
Not sure, nevertheless, if Scopus/Duet oligonucleotide TLR9 technology were able to be applied to vaccines (like covid 19 vaccines) = additional monumental potential.
Hopefully some answers to that next Friday September 10/21
Candida:
https://www.healthline.com/nutrition/candida-symptoms-treatment
https://www.webmd.com/skin-problems-and-treatments/guide/what-is-candidiasis-yeast-infection
Interesting article from researchers in The Netherlands and Germany.
https://www.news-medical.net/news/20210510/Research-suggests-Pfizer-BioNTech-COVID-19-vaccine-reprograms-innate-immune-responses.aspx
"In contrast, responses to the fungal pathogen Candida albicans were higher after vaccination.
In addition, the production of the anti-inflammatory cytokine interleukin-1Ra was reduced in response to Toll-like receptor 4 and C. albicans. This also suggests a shift towards increased inflammatory responses to fungi following vaccination, say the researchers."
"14th Annual RNA Consortium Meeting, to be held virtually on Friday, September 10, 2021."
https://finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-therapeutics-132500208.html
"Dr. Horsager’s presentation will be part of the Clinical Translation of Oligonucleotide Therapeutics session. Dr. Horsager will present on Clinical Development of CpG-STAT3 Inhibitors."
Phase I results incoming, imho.
News Release September 2/21
https://finance.yahoo.com/news/scopus-biopharma-launches-duet-therapeutics-131500733.html
(Possible game changing technology here, imho)
"The Duet Platform is comprised of three complementary, underpinning technologies:
•RNA silencing
CpG-STAT3siRNA
(“DUET-01”)
•Antisense
CpG-STAT3ASO
(“DUET-02”)
•Protein degradation
CpG-STAT3decoy
(“DUET-03”)
Dr. Horsager added, “The unique mechanism-of-action of these synthetic oligos comes from simultaneously targeting two intracellular immune pathways, STAT3 and TLR9. The targeted inhibition of STAT3, a master immune checkpoint inhibitor, reawakens immune cells and allows for the full potential of TLR9-driven immune responses.”"
Not sure why the annual meeting was changed to October 8.
Just speculation here, would it be possible that some preliminary results from Phase 1 might be a subject of discussion at such an annual meeting?
Phase 1 generally studies dosage safety and can range from weeks to months to complete.
Phase 1, i believe has been underway since May/21.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
102
|
Created
|
06/09/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |